Pradaxa® is a simple treatment option that is as effective as warfarin with significantly lower bleeding rates, a major advance for DVT and PE patients 1–4 EU approval follows recent U.S. FDA approval ...

Data from key trials will aid in increasing scientific understanding of ESUS and CVT RESPECT-ESUS is first randomised trial to investigate clinical profile of Pradaxa ® vs ASA INGELHEIM, ...

A concentrated form of prothrombin complex appears to rapidly and permanently reverse the effects of the novel anticoagulant rivaroxaban, a factor Xa inhibitor. But according to results of a small ...

Combination NOAC therapy. The data suggest possible variability across NOACs regarding gastrointestinal bleeding risk, with an increased risk associated with rivaroxaban and dabigatran. Non–vitamin K ...

LOS ANGELES, CA—Another real-world study has suggested that there may be differences among the non-vitamin K antagonist oral anticoagulants (NOACs) in terms of the risk of major bleeding. Among ...

RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® dual therapy was used instead of warfarin triple therapy Both Pradaxa® doses tested in RE-DUAL PCI™ have ...

Use of the novel oral anticoagulants dabigatran and rivaroxaban is contraindicated in patients undergoing dialysis because the drugs can bioaccumulate and cause increased bleeding. Dabigatran and ...

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism Three pivotal trials showed PRADAXA as ...

In 2010, the blood thinner dabigatran (brand name Pradaxa) was approved by the U.S. Food and Drug Administration as a treatment option for people with atrial fibrillation. Dabigatran was at least as ...

Boehringer Ingelheim, on the defense about the anticoagulant Pradaxa for some time over bleeding concerns, went on the offensive this week, reporting results from studies that the drugmaker says ...

RIDGEFIELD, Conn., March 19, 2017 /PRNewswire/ -- Important new data from the RE-CIRCUIT® study show a better safety profile for Pradaxa® (dabigatran etexilate mesylate) compared to warfarin in atrial ...